Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Android version of the Tandem Mobi mobile app.
Tandem Mobi, the world’s smallest, durable automated insulin delivery system , is powered by Control-IQ+ technology. Proven Control-IQ+ benefits include:
- Day 1 improvements2
- 79% time in range3
- 90% overnight time in range4
“We’re excited to bring Tandem Mobi and the best-in-class outcomes of Control-IQ+ to Android users,” said John Sheridan, president and chief executive officer. “This latest integration gives Android users access to the life-changing benefits of Control-IQ+ on a system that emphasizes convenience, discretion, and customization.”
The Tandem Mobi mobile app is a secure, user-friendly mobile application designed to seamlessly pair with the Tandem Mobi insulin pump. It enables users to manage their diabetes directly from their personal, compatible smartphone, which will now include Android devices. The app’s intuitive interface and secure connectivity to the Tandem Source platform helps support better engagement between patients and their healthcare providers, facilitating more informed treatment decisions and improved outcomes.
“With the Tandem Mobi mobile app, we’re delivering a solution that meets patients where they are, on the devices they use every day, while maintaining the safety, reliability, and innovation they expect from Tandem,” said Dr. Jordan Pinsker, chief medical officer.
A limited release is expected to start in December 2025, followed by commercial availability in early 2026. Once available, the Tandem Mobi Android app will be downloadable from the Google Play Store on compatible smartphones, including Google Pixel models 6 through 10 and Samsung Galaxy models S21 through S25. A full compatibility list will be published closer to commercial availability.
